Commentary: Metabolic Effects of Treatment
With Atypical Antipsychotics
Read the Commentary [PDF]
See this commentary in the context of the November CME activity.
Introduction [audio]
The Prevalence of Obesity and Type 2 Diabetes in the Population of Patients Who Are Treated With Antipsychotic Medications [audio]
Antipsychotic Medications and an Increase of Rates of Obesity, Type 2 Diabetes, and Dyslipidemia [audio]
Evaluation of Differences in Risk Among Atypical Antipsychotics [audio]
Other Factors That Contribute to an Increased Risk of Metabolic Syndrome Among Psychiatric Patients Receiving Atypical Antipsychotics [audio]
Strategies to Prevent or Minimize Metabolic Effects [audio]
Monitoring of Metabolic Effects in Patients Taking Antipsychotic Medications [audio]
Changing Patients' Medication Because of Adverse Metabolic Effects [audio]
John M. Kane, M.D.; Eugene J. Barrett, M.D., Ph.D.; Daniel E. Casey, M.D.; Christoph U. Correll, M.D.; Alan J. Gelenberg, M.D.; Samuel Klein, M.D.; and John W. Newcomer, M.D.

Physicians Discuss the Consensus Statement on Antipsychotic Medications and Obesity and Diabetes

In addition to the text of the Commentary, you can also listen to the discussion by following the audio links to the left. The audio presentations are in Macromedia Flash. See our Online Media Page for more information.

Faculty disclosure: In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this CME activity were asked to complete a full disclosure statement. The information received is as follows: Dr. Kane is a consultant for Abbott, Pfizer, Johnson & Johnson, Eli Lilly, and Janssen and is a member of the speakers/advisory board for Bristol-Myers Squibb, AstraZeneca, Lundbeck, Novartis, and Janssen. Dr. Barrett is a consultant for Pfizer, Bristol-Myers Squibb, and GlaxoSmithKline. Dr. Casey is a consultant for Abbott, AstraZeneca, Aventis, Bristol-Myers Squibb, Janssen, Eli Lilly, Novartis, Pfizer, and Sumitomo; and is a member of the speakers/advisory board for Abbott, Bristol-Myers Squibb, Janssen, Eli Lilly, Ortho-McNeil, and Pfizer. Dr. Correll is a member of the speakers/advisory board for Janssen, AstraZeneca, and Bristol-Myers Squibb. Dr. Gelenberg is a consultant for Eli Lilly, Pfizer, Vela Pharmaceuticals, Best Practice, Bristol-Myers Squibb, AstraZeneca, Wyeth, GlaxoSmithKline, Cyberonics, Roche, ZARS, Express Scripts, and Janssen; has received grant/research support from Pfizer and Wyeth; and is a member of the speakers' bureau for Wyeth, Cyberonics, and Pfizer. Dr. Klein has received grant/research support from Transneuronix; has received honoraria from Merck; and is a member of the advisory board for Roche and Enteromedics. Dr. Newcomer is a consultant for Janssen, Eli Lilly, Pfizer, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, and Wyeth; has received grant/research support from Janssen, Eli Lilly, Pfizer, AstraZeneca, and Bristol-Myers Squibb; and has received speaking honoraria from Janssen, Pfizer, AstraZeneca, Bristol-Myers Squibb, and Sanofi-Synthelabo.
 

Disclosure of off-label usage: The chair has determined that, to the best of his knowledge, no investigational information about pharmaceutical agents has been presented in this article that is outside U.S. Food and Drug Administration-approved labeling.